Unlock the Future of Type 2 Diabetes Care (featuring Dr. Viral Shah)

By Omnipod® FEATURING Viral Shah
By Omnipod® FEATURING Viral Shah
134 views
September 12, 2024

Dive into the groundbreaking SECURE T2D study, the largest and most diverse trial ever conducted on Automated Insulin Delivery (AID) for people with type 2 diabetes. Discover how Omnipod 5 demonstrated improvements in A1C levels, increased time in range (TIR), and participant-reported reduction in Diabetes Distress. Dr. Viral Shah from the Indiana University School of Medicine, and an investigator in this trial, reveals key insights on how Omnipod 5 can help simplify diabetes management.

Don’t miss this chance to learn how Omnipod 5 can enhance your care for your patients living with type 2 diabetes.

Risk Statement

Training is essential and must be completed before a patient starts using the Omnipod 5 System. As part of this process, you will need to meet with your patient to initiate and adjust their settings. They must also visit omnipod.com/setup to complete setup and schedule their required training. Omnipod 5 System Overview for HCPs: https://insulet.wistia.com/medias/jli756jpqx

Omnipod 5 for HCPs: https://www.omnipod.com/hcp/products/omnipod5

The Omnipod 5 Automated Insulin Delivery (AID) System is cleared for individuals with type 1 diabetes ages 2 and older & type 2 diabetes ages 18 and older. The Omnipod 5 System is intended for single patient, home use and requires a valid prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery User Guide and omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. To use Omnipod 5 in Automated Mode, the Dexcom G6 or Dexcom G7 mobile app is required. The Dexcom G6 or Dexcom G7 are not included in the Omnipod 5 System and require a separate prescription. The Dexcom G6 and G7 receivers are not compatible.

0 Comments
Login to view comments. Click here to Login